Posters presented at CROI 2026 highlight the safe use of tirzepatide in patients with HIV.
AJMC news story
The recent approval of tirzepatide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA) to treat obesity and diabetes has made it a hot-button topic among researchers for use in other areas, including obstructive sleep apnea, cardiovascular disease, and chronic kidney disease. However, its use in patients with HIV, a group of patients who see a higher rate of diabetes compared with the general population, has been less studied due to the recency of the approvals. Posters presented at CROI 2026 featured research on the efficacy of tirzepatide in managing diabetes and weight in patients living with HIV.
Read the full news story here.
View all AJMC reports from CROI 2026
Source : AJMC
Related HIV and Co-Infections News
-
CATIE: Long American study explores trends in dementia among people with and without HIV
-
[Press release] LSHTM: Community-based integrated care for HIV, diabetes and hypertension safely expands access while easing pressure on health facilities in sub-Saharan Africa
-
Infectious Disease Advisor: Long-acting CAB plus RPV maintains HIV suppression in patients with obesity
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.